暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股市場個股詳情
HUGE FSD Pharma
- 0.3754
- -0.0321-7.88%
收盤價 05/01 16:00 (美東)
- 0.3600
- -0.0154-4.10%
盤後 19:57 (美東)
1517.73萬總市值-816市盈率TTM
0.4299最高價0.3557最低價65.89萬股成交量0.4200今開0.4075昨收25.31萬成交額1.90%換手率虧損市盈率(靜)4042.96萬總股本1.679952周最高1.15市淨率1300.85萬流通值0.355752周最低--股息TTM3465.23萬流通股14.0000歷史最高--股息率TTM18.22%振幅0.3557歷史最低0.3840平均價1股每手
全部分時
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
資金分布
單位: --
資金流向
實時日周月
暫無數據
新聞
快訊 | “解密大麻仍使大麻庫存陷入困境”-《華爾街日報》
FSD Pharma Trials 酒精中毒補充劑
緝毒局開始將大麻重新歸類爲危險性較低的藥物
緝毒局開始將大麻重新歸類爲危險性較低的藥物
FSD Pharma與應用科學與性能研究所簽署協議，在美國進行一項臨床試驗，以評估 “Unbuzzd” 在酒精中毒誘發狀態下的安全性和有效性
FSD Pharma Inc.（納斯達克股票代碼：HUGE）（CSE: HUGE）（FRA: 0K9A）（“公司” 的 “FSD Pharma”），一家致力於爲該療法建立創新資產和生物技術解決方案組合的生物製藥公司
快訊 | 關注大麻股票的股票；交易員在TDR播客中發表評論說：“我們聽說有傳言稱該公告可能在本週發佈——不管做出什麼決定”，“我從一些消息來源聽說支持大麻的消息
FSD Pharma表示，Celly Nutrition與Six+One合作在美國推出膳食補充劑
FSD Pharma（HUGE）週四表示，Celly Nutrition已與品牌機構Six+One合作，合作在美國推出其膳食補充劑。作爲合作的一部分，
評論
$FSD Pharma(HUGE.US$
NEWS
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
NEWS
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
$FSD Pharma(HUGE.US$ This sure was a disappointment! But its green! And thats sure better than red by any amount 
2
Update
$FSD Pharma(HUGE.US$ FSD Pharma Provides Update From Celly Nu's Partnership With Six+One For Beverage Product Unbuzzd
Benzinga· 8 mins ago
On April 25, 2024, Celly Nu announced a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City.
FSD Pharma has also licensed unbuzzd, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving indiv...
Benzinga· 8 mins ago
On April 25, 2024, Celly Nu announced a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City.
FSD Pharma has also licensed unbuzzd, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving indiv...
$FSD Pharma(HUGE.US$
NEWS
FSD Pharma Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them a 180-day compliance period to meet the requirement or face potential delisting.
NEWS
FSD Pharma Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them a 180-day compliance period to meet the requirement or face potential delisting.
Update
$FSD Pharma(HUGE.US$ FSD Pharma Brief: Signed Agreement With INGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
閱讀更多
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅